Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Author(s): Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D

Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

Subject: Schizophrenia View the study

Abstract:

Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermore, enhanced anandamide signaling let to a lower transition rate from initial prodromal states into frank psychosis as well as postponed transition. In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings.

Source: Translational Psychiatry
Share Tweet

More medical studies related to Schizophrenia:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

читайте на сайте

details

ссылка progressive.ua